Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

29.95USD
4:00pm EDT
Price Change (% chg)

$0.11 (+0.37%)
Prev Close
$29.84
Open
$30.05
Day's High
$30.19
Day's Low
$29.81
Volume
7,690,920
Avg. Vol
6,019,326
52-wk High
$32.96
52-wk Low
$27.51

PFE.N

Chart for PFE.N

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.70
Market Cap (Mil.): $189,211.41
Shares Outstanding (Mil.): 6,340.86
Dividend: 0.26
Yield (%): 3.49

Financials

  PFE.N Industry Sector
P/E (TTM): 18.43 32.70 33.67
EPS (TTM): 1.62 -- --
ROI: -- 18.12 17.39
ROE: -- 18.79 18.21
Search Stocks

Pfizer meningitis vaccine wins U.S. approval

- Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis B, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday.

29 Oct 2014

UPDATE 2-Pfizer meningitis vaccine wins U.S. approval

Oct 29 - Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis B, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday.

29 Oct 2014

Pfizer meningitis vaccine wins U.S. approval- FDA

Oct 29 - Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday.

29 Oct 2014

Pfizer executives: new Treasury rules hamstring inversion deals

NEW YORK - Pfizer Inc's finance chief said on Tuesday that new rules by the U.S. Treasury will make it "prohibitively harder" for American companies to buy foreign firms in order to relocate to lower-tax jurisdictions.

28 Oct 2014

BRIEF-Pfizer CEO says inversion deals still one potential option for company

Oct 28 - Pfizer Inc : * CEO says inversion deals still one potential option for company * CEO says still believes tax inversion deals, on case by case basis, can offer

28 Oct 2014

Pfizer beats sales and profit forecasts, mum on future deals

- Pfizer Inc reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc .

28 Oct 2014

UPDATE 2-Pfizer beats sales and profit forecasts, mum on future deals

(Adds CEO, analyst comment, looming patent expirations, shares)

28 Oct 2014

Pfizer beats Q3 forecasts, mum on likely future deals

Oct 28 - Pfizer Inc reported better than expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans in the wake of its recent failed efforts to buy rival British drugmaker AstraZeneca Plc.

28 Oct 2014

Pfizer ends deal with Pain Therapeutics to develop Durect's pain drug

- Pfizer Inc ended an agreement with Pain Therapeutics Inc to develop and market Durect Corp's pain drug, Remoxy, sending the stocks of the two smaller drugmakers plummeting.

27 Oct 2014

Pfizer ends deal with Pain Therapeutics to develop Durect's pain drug

Oct 27 - Pfizer Inc ended an agreement with Pain Therapeutics Inc to develop and market Durect Corp's pain drug, Remoxy, sending the stocks of the two smaller drugmakers plummeting.

27 Oct 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $107.78 +0.74
Novartis AG (NOVN.VX) CHF89.30 +1.60
Merck & Co., Inc. (MRK.N) $57.94 +0.63
Roche Holding Ltd. (ROG.VX) CHF283.70 +0.30
Abbott Laboratories (ABT.N) $43.59 +0.10
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.66 +1.75
AstraZeneca plc (AZN.L) 4,543.50p +43.50
GlaxoSmithKline plc (GSK.L) 1,417.50p +19.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks